Determination of globotriaosylceramide in plasma and urine by mass spectrometry

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 2, 2010, Pages 189-198

  Krüger, Ralf ^a   Bruns, Kai ^a,b   Grünhage, Silke ^a   Rossmann, Heidi ^a   Reinke, Jörg ^a   Beck, Michael ^a   Lackner, Karl J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Fabry disease; Gb3 (globotriaosylceramide); Glycosphingolipid; Liquid chromatography tandem mass spectrometry; Lysosomal storage disorder

Indexed keywords

EDETIC ACID; GLOBOTRIAOSYLCERAMIDE; ISOPROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CALIBRATION; CHILD; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; FABRY DISEASE; FEMALE; FLOW INJECTION ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMA; PRECIPITATION; PRIORITY JOURNAL; PURIFICATION; SOLID PHASE EXTRACTION; URINE; VALIDATION STUDY;

ALPHA-GALACTOSIDASE; CALIBRATION; CHROMATOGRAPHY, LIQUID; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; LYSOSOMAL STORAGE DISEASES; MALE; REFERENCE STANDARDS; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; TRIHEXOSYLCERAMIDES;

EID: 76649134434     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.048     Document Type: Article

References (39)

1. Brady RO. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967;276:1163-1167
2. Fabry H. An historical overview of Fabry disease. J Inherit Metab Dis 2001;24(Suppl 2):3-7.
3. Clarke JT. Narrative review: Fabry disease. Ann Intern Med 2007;146:425-433
4. Eng CM, Desnick RJ. Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene. Hum Mutat 1994;3:103-111
5. Garman SC, Garboczi DN. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol 2004;337:319-335
6. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338-346
7. Hauser AC, Lorenz M, Sunder-Plassmann G. The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy. J Intern Med 2004;255:629-636
8. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-760 (Pubitemid 33032930)
9. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-775 (Pubitemid 33032933)
10. Rolfs A, Böttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005;366: 1794-1796
11. Vedder AC, Linthorst GE, Van Breemen MJ, Groener JE, Bemelman FJ, Strylond A, et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 2007;30:68-78.
12. Auray-Blais C, Cyr D, Ntwari A, West ML, Cox-Brinkman J, Bichet DG, et al. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab 2008;93:331-340
13. Kitagawa T, Ishige N, Suzuki K, Owada M, Ohashi T, Kobayashi M, et al. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Mol Genet Metab 2005;85:196-202.
14. Beck M. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet 2007;121:1-22.
15. Vance DE, Sweeley CC. Quantitative determination of the neutral glycosyl ceramides in human blood. J Lipid Res 1967; 8:621-630
16. Gross SK, McCluer RH. High-performance liquid chromatographic analysis of neutral glycosphingolipids as their per-Obenzoyl derivatives. Anal Biochem 1980;102:429-433
17. Hazumi I, Nishizawa M, Ariga T, Miyatake T. Biochemical and clinical analysis of accumulated glycolipids in symptomatic heterozygotes of angiokeratoma corporis diffusum (Fabry's disease) in comparison with hemizygotes. J Lipid Res 1990; 31:335-340
18. Kniep B, Mühlradt PF. Immunochemical detection of glycosphingolipids on thin-layer chromatograms. Anal Biochem 1990;188:5-8.
19. Groener JE, Poorthuis BJ, Kuiper S, Helmond MT, Hollak CE, Aerts JM. HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma. Clin Chem 2007;53:742-747
20. Ullmann MD, McCluer RH. Quantitative microanalysis of perbenzoylated neutral glycosphingolipids by high-performance liquid chromatography with detection at 230 nm. J Lipid Res 1978;19:910-913
21. Lee WM, Westrick MA, Macher BA. High-performance liquid chromatography of long-chain neutral glycosphingolipids and gangliosides. Biochim Biophys Acta 1982;7:498-504.
22. Strasberg PM, Warren I, Skomorowski MA, Lowden JA. HPLC analysis of neutral glycolipids: an aid in the diagnosis of lysosomal storage disease. Clin Chim Acta 1983;132:29-41.
23. Roy S, Gaudin K, Germain DP, Baillet A, Prognon P, Chaminade P. Optimisation of the separation of four major neutral glycosphingolipids: application to a rapid and simple detection of urinary globotriaosylceramide in Fabry disease. J Chromatogr B 2004;805:331-337
24. Berná L, Asfaw B, Conzelmann E, Cerný B, Ledvinova J. Determination of urinary sulfatides and other lipids by combination of reversed-phase and thin-layer chromatographies. Anal Biochem 1999;269:304-311
25. Zeidner KM, Desnick RJ, Ioannou YA. Quantitative determination of globotriaosylceramide by immunodetection of glycolipid- bound recombinant verotoxin B subunit. Anal Biochem 1999;267:104-113
26. Nakanishi T, Funahashi S, Funai T, Hashimoto T, Shimizu A. Chemical diagnosis of Fabry's disease by fluorometric assay and fast atom bombardment/mass spectrometry. Ann Clin Biochem 1991;28:368-372
27. Touboul D, Roy S, Germain DP, Baillet A, Brion F, Prognon P, et al. Fast fingerprinting by MALDI-TOF mass spectrometry of urinary sediment glycosphingolipids in Fabry disease. Anal Bioanal Chem 2005;382:1209-1216
28. Mills K, Johnson A, Winchester B. Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry. FEBS Lett 2002;515:171-176
29. Boscaro F, Pieraccini P, La Marca G, Bartolucci G, Luceri L, Luceri F, et al. Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease. Rapid Commun Mass Spectrom 2002;16:1507-1514
30. Fauler G, Rechberger GN, Devrnja D, Erwa W, Plecko B, Kotanko P, et al. Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35- globotriaosylceramide as internal standard. Rapid Commun Mass Spectrom 2005;19:1499-1506
31. Whitfield PD, Calvin J, Hogg S, O'Driscoll E, Halsall D, Burling K, et al. Monitoring enzyme replacement therapy in Fabry disease - role of urine globotriaosylceramide. J Inherit Metab Dis 2005;28:21-33.
32. Nelson BC, Roddya T, Araghi S, Wilkens D, Thomas JT, Zhang K, et al. Globotriaosylceramide isoform profiles in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B 2004;805:127-134
33. Mills K, Vellodi A, Morris P, Cooper D, Morris M, Young E, et al. Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease. Eur J Pediatr 2004;163:595-603.
34. Mills K, Morris P, Lee P, Vellodi A, Waldek S, Young E, et al. Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease. J Inherit Metab Dis 2005;28:35-48.
35. Nelson C, Sung CC, Araghi S, Wilkens D, Zhang K, Thomas JJ, et al. Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy. Clin Chem 2005;51:237-240
36. Delobel A, Roy S, Touboul D, Gaudin K, Germain DP, Baillet A, et al. Atmospheric pressure photoionization coupled to porous graphitic carbon liquid chromatography for the analysis of globotriaosylceramides. Application to Fabry disease. J Mass Spectrom 2006;41:50-58
37. Mehta A, Ricci R, Widmer U, Dehout F, Garcia De Lorenzo A, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-242
38. Deegan PB, Baehner AF, Barba Romero MÁ , Hughes DA, Kampmann C, Beck M, et al. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006; 43:347-352
39. Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 2006;95:86-92. (Pubitemid 43041735)